Key Drivers
- Liquidity Buffer
- Severe Cash Burn
- Equity Dependence
AIAI Summary
BHVN is now best viewed as a binary catalyst-driven biotech rather than a simple cash burn story: improved liquidity and advancing late-stage programs buy time, but the stock likely depends on strong upcoming readouts to re-rate before ongoing burn and dilution consume the upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Buffer
- •Severe Cash Burn
- •Equity Dependence
BHVN's balance sheet has strengthened sharply with ample cash coverage and minimal net debt, but persistent revenue-free operations, heavy R&D spend, and steep cash burn mean it remains highly dependent on outside financing.
Price Behavior
Key Price Behavior Insights:
- •Broken support
- •Lower highs
- •Range floor
BHVN remains in a clear short-term downtrend after falling about 20% over the last month, losing $9.20 support and now trying to stabilize near $8.75–$9.00.
Rebounds stalled below $10.00 after a sharp drop from the recent high
Sentiment & News
Key News Insights:
- •Q1 Update
- •Opakalim Data
- •R&D Day
Biohaven's recent updates and Buy upgrade highlight strengthening sentiment as it advances late-stage epilepsy programs, with opakalim topline data expected in 2H 2026 and key clinical/regulatory milestones ahead.
The news is modestly positive for BHVN, as it reinforces near-term catalysts and improves visibility on pipeline execution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings